PMID- 29152113
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 50
DP  - 2017 Oct 20
TI  - The prognostic significance of MCL1 copy number gain in esophageal squamous cell 
      carcinoma.
PG  - 87699-87709
LID - 10.18632/oncotarget.21181 [doi]
AB  - BACKGROUND: MCL1 copy number variations have been reported to be associated with 
      cancer prognosis in several cancers. However, the role of MCL1 gain has not yet 
      been determined in esophageal squamous cell carcinomas (ESCC). METHODS: 
      Fluorescence in situ hybridization (FISH) for MCL1 was performed on 262 ESCC 
      samples using tissue microarray (TMA). RESULTS: The median age of ESCC patients 
      was 62 years (range 37-83), with frequencies between women (16.4%) and men 
      (83.6%). Of the 262 tumors, 77 tumors (29.4%) had high MCL1 gain. In the 
      multivariate analysis, lymph node metastasis (HR: 3.236, P<0.001 for DFS; HR: 
      3.501, P<0.001 for OS) and clinical stage (HR: 3.388, P<0.001 for DFS; HR: 3.616, 
      P<0.001 for OS) were identified as independent worse prognostic factors. 
      Interestingly, among patients without lymph node metastasis or stage I-II 
      patients, high MCL1 gain was associated with better DFS (P=0.009 or 0.046) and OS 
      (P=0.014 or 0.069) after disease free survival time was more than or equal to 12 
      months. Reversely, among patients with lymph node metastasis or stage III-IVa 
      patients, high MCL1 gain was associated with poorer DFS (P=0.007 or 0.021) and OS 
      (P=0.029 or 0.068) after disease free survival time was more than or equal to 29 
      months. CONCLUSION: We observed that high MCL1 gain had bidirectional prognostic 
      significance in ESCC patients with different lymph node status or clinical stage. 
      These findings might provide the useful way of detailed risk stratification in 
      patients with ESCC, and an insight into pathogenesis and mechanism of progression 
      in ESCC.
FAU - Xu, Chen
AU  - Xu C
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, 
      P. R. China.
FAU - Liu, Yalan
AU  - Liu Y
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, 
      P. R. China.
FAU - Huang, Jie
AU  - Huang J
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, 
      P. R. China.
FAU - Wang, Hao
AU  - Wang H
AD  - Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 
      200032, P. R. China.
FAU - Tan, Lijie
AU  - Tan L
AD  - Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 
      200032, P. R. China.
FAU - Xu, Yifan
AU  - Xu Y
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, 
      P. R. China.
FAU - Jiang, Zhengzeng
AU  - Jiang Z
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, 
      P. R. China.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, 
      P. R. China.
FAU - Hou, Yingyong
AU  - Hou Y
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, 
      P. R. China.
AD  - Department of Pathology, School of Basic Medical Sciences & Zhongshan Hospital, 
      Fudan University, Shanghai 200032, P. R. China.
FAU - Jiang, Dongxian
AU  - Jiang D
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, 
      P. R. China.
FAU - Wang, Qun
AU  - Wang Q
AD  - Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 
      200032, P. R. China.
LA  - eng
PT  - Journal Article
DEP - 20170923
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5675665
OTO - NOTNLM
OT  - ESCC
OT  - MCL1 copy number gain
OT  - clinical stage
OT  - lymph node metastasis
OT  - prognostic marker
COIS- CONFLICTS OF INTEREST Authors have no conflicts to disclose for this 
      study/manuscript.
EDAT- 2017/11/21 06:00
MHDA- 2017/11/21 06:01
PMCR- 2017/10/20
CRDT- 2017/11/21 06:00
PHST- 2016/11/14 00:00 [received]
PHST- 2017/08/26 00:00 [accepted]
PHST- 2017/11/21 06:00 [entrez]
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2017/11/21 06:01 [medline]
PHST- 2017/10/20 00:00 [pmc-release]
AID - 21181 [pii]
AID - 10.18632/oncotarget.21181 [doi]
PST - epublish
SO  - Oncotarget. 2017 Sep 23;8(50):87699-87709. doi: 10.18632/oncotarget.21181. 
      eCollection 2017 Oct 20.